Private equity opportunities in Japan for investors
Private equity is eyeing up the country and moving in to break apart giants. That will be great for investors, says Matthew Lynn.
The deal may still fall apart at the last minute. The government may step in to block it. Shareholders may get cold feet. But the takeover of the Japanese conglomerate Toshiba by the buyout giant Bain Capital looks close to completion.
If it happens, it will be among the largest buyouts of a listed company ever staged. It could also pave the way for a series of buyouts of Japan’s ageing, uncompetitive conglomerates, opening up a huge range of opportunities for their global competitors and for investors as well. Toshiba has a long and distinguished history stretching back to the 1870s, but it has been in trouble for years.
It has been beset by a series of accounting scandals, management upheavals and troubled takeovers, while competition in many of its main markets has been getting fiercer, which forced it to slim down and retrench. If you wanted to write a textbook on ineptly managed conglomerates, you couldn’t ask for a more perfect case study. Bain’s offer will probably come as a relief to shareholders and indeed to management, even in Japan, where takeovers, and foreign ones especially, have always been disapproved of.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The first of a wave of deals
In itself it will be a huge deal. When, and if, a final price is agreed, Toshiba is likely to cost Bain at least $20bn, putting it in the top 20 buy-out deals of all time. So long as it has a free hand, Bain should be able to make plenty of money on that investment. Toshiba, like many Japanese companies, has a sprawling range of units, ranging from air conditioners to consumer electronics to medical equipment, office systems, and IT management. There are probably dozens of little businesses within it that just need capitalising, some fresh ideas, a burst of energy, and can suddenly be brought back to health and sold off at a big profit.
It will certainly be a lot easier to make money from Toshiba than from a business such as Morrisons, sold to private equity for a fat price last year, which is already very efficiently run and operating in a very competitive market.
The deal may well open the door to a wave of private-equity deals in Japan. If so, that will be a unique opportunity and one of the most compelling of the 2020s. Japan has lots of great businesses that are ripe for a shake-up. Sony would be a very tempting target for one of the tech giants. Toyota is one of the best carmakers in the world and its two domestic rivals, Mazda and Honda, have fantastic niches and strong reputations. Takeda has formidable drugs research ,distribution, and manufacturing in its domestic market, and would surely be a tempting acquisition for Pfizer, GlaxoSmithKline and AstraZeneca, especially if it was broken up into separate units.
Japan also has lots of vast, sprawling conglomerates of the sort that were all broken up in the US and UK 30 years ago. There are companies we have hardly heard of, such as Itochu, with a value of more than $50bn, which has six divisions from food to textiles, all of which could be knocked briskly into far better shape and then listed as separate companies, or sold off to their global rivals.
Rich pickings for investors
There are three broader opportunities that the Toshiba deal can unlock. For the giant buyout firms, Japan could open up a whole new wave of potential targets, and at precisely the time when traditional hunting grounds such as the UK and US were starting to look difficult. It will take a lot of capital – not many Japanese conglomerates will cost less than the $20bn Toshiba is likely to command – but the returns will be handsome. Second, there will be opportunities for some of the world’s biggest companies to pick up choice businesses in food, consumer goods, engineering and electronics as units get spun out of the conglomerates that controlled them. This could boost earnings and market share. And finally, there will be plenty for shareholders. If the private-equity firms rip through Japan, the market will finally start to deliver after three decades of dismal returns, and the buyout funds will be a pretty good bet as well.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew Lynn is a columnist for Bloomberg and writes weekly commentary syndicated in papers such as the Daily Telegraph, Die Welt, the Sydney Morning Herald, the South China Morning Post and the Miami Herald. He is also an associate editor of Spectator Business, and a regular contributor to The Spectator. Before that, he worked for the business section of the Sunday Times for ten years.
-
UK dividends rose in final quarter of 2025, but share buybacks ate into investor payoutsLast year saw dividend growth continue to fall below pre-pandemic averages, against a backdrop of increasing share buybacks.
-
Lifetime ISA reform: Retirement option could be scrapped in overhaulA consultation on a product replacing the Lifetime ISA is set to be launched this year, and the option to use it to save for retirement is expected to be axed in the shake-up
-
Three promising emerging-market stocks to diversify your portfolioOpinion Omar Negyal, portfolio manager, JPMorgan Global Emerging Markets Income Trust, highlights three emerging-market stocks where he’d put his money
-
Coface offers excess profit in an unloved sectorCoface is a world leader in trade-credit insurance with key competitive advantages in a niche market
-
Exciting opportunities in biotechBiotech firms should profit from the ‘patent cliff’, which will force big pharmaceutical companies to innovate or make acquisitions
-
How to invest in the new breed of payment providersUpstart payment providers are taking the world by storm. It’s time for investors to buy in, says Rupert Hargreaves
-
What turns a stock market crash into a financial crisis?Opinion Professor Linda Yueh's popular book on major stock market crashes misses key lessons, says Max King
-
How to add cryptocurrency to your portfolioA new listing shows how bitcoin might add value to a portfolio if cryptocurrency keeps gaining acceptance, says Cris Sholto Heaton
-
Profit from pest control with Rentokil InitialRentokil Initial is set for global expansion and offers strong sales growth
-
Three funds to buy for capital growth and global incomeOpinion Three investment trusts with potential for capital growth, selected by Adam Norris, co-portfolio manager of the CT Global Managed Portfolio Trust